Serum apolipoprotein A1 rather than apolipoprotein B is associated with hypertension prevalence in Chinese people with coronary artery disease.
Journal
Blood pressure monitoring
ISSN: 1473-5725
Titre abrégé: Blood Press Monit
Pays: England
ID NLM: 9606438
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
pubmed:
8
12
2021
medline:
8
3
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
Studies on the association of apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) with hypertension (HTN) prevalence in patients with coronary artery disease (CAD) are limited. This cross-sectional study aimed to investigate this association in Chinese people in Wuhan, China. Serum ApoA1 and ApoB levels were measured by immunoturbidimetry assay. Logistic regression analysis was used to estimate the associations of ApoA1 and ApoB level and ApoB/A1 ratio with HTN prevalence. We included 5192 individuals (3060 men, mean age 61 years; 4412 HTN cases) in this study. After adjusting for covariates, serum ApoA1 but not ApoB level or ApoB/A1 ratio was inversely associated with HTN prevalence. HTN prevalence was reduced with the fifth versus first quintile of ApoA1 level [odds ratio = 0.78 (95% confidence interval 0.62-0.98)]. In stratified analyses based on sex, the probability of HTN with the fifth versus first ApoA1 level was 0.71 (0.53-0.96) for men. The probability of HTN with the fifth versus first quintile of ApoB/A1 ratio was 1.54 (1.11-2.13) after adjustment. With quintiles 2-5 versus of ApoB level, the probability of HTN did not differ in both men and women. On path analyses, the association of ApoA1 level and ApoB/A1 ratio with HTN was mediated by BMI (β coefficients: -0.179 to 0.133). In general, high serum ApoA1 level may be associated with a reduced probability of HTN prevalence in patients with CAD in China, and this association may be mediated by BMI.
Identifiants
pubmed: 34873074
doi: 10.1097/MBP.0000000000000576
pii: 00126097-202204000-00007
doi:
Substances chimiques
Apolipoprotein A-I
0
Apolipoproteins B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-127Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117–171.
Hu ST, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, et al. Summary of the 2018 report on cardiovascular diseases in China. Chin Circ J 2019; 34:209–219.
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224–2260.
Escobar E. Hypertension and coronary heart disease. J Hum Hypertens 2002; 16 (Suppl 1):S61–S63.
Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol 2007; 18:633–637.
Domingo-Espín J, Nilsson O, Bernfur K, Del Giudice R, Lagerstedt JO. Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism. Biochim Biophys Acta Mol Basis Dis 2018; 9:23.
Fritzen AM, Domingo-Espín J, Lundsgaard AM, Kleinert M, Israelsen I, Carl CS, et al. ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα2. Mol Metab 2020; 35:100949.
Meriwether D, Sulaiman D, Volpe C, Dorfman A, Grijalva V, Dorreh N, et al. Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J Clin Invest 2019; 129:3670–3685.
Skogsberg J, Dicker A, Rydén M, Aström G, Nilsson R, Bhuiyan H, et al. ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes. PLoS One 2008; 3:e3771.
Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther 2009; 123:281–291.
Lee JY, Kang MJ, Choi JY, Park JS, Park JK, Lee EY, et al. Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis. Ann Rheum Dis 2018; 77:1480–1489.
Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJ. Familial hypercholesterolemia in children. Curr Opin Lipidol 2004; 15:405–411.
Sniderman AD, Marcovina SM. Apolipoprotein A1 and B. Clin Lab Med 2006; 26:733–750.
van der Vorst EPC. High-density lipoproteins and apolipoprotein A1. Subcell Biochem 2020; 94:399–420.
Pastore L, Belalcazar LM, Oka K, Cela R, Lee B, Chan L, Beaud AL. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 2004; 327:153–160.
Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, et al. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 2014; 130:776–785.
Reena, Kaur T, Kaur A, Singh M, Buttar HS, Pathak D, et al. Mast cell stabilizers obviate high fat diet-induced renal dysfunction in rats. Eur J Pharmacol 2016; 777:96–103.
Wu BJ, Sun Y, Ong KL, Li Y, Tang S, Barter PJ, Rye KA. Apolipoprotein A-I protects against pregnancy-induced insulin resistance in rats. Arterioscler Thromb Vasc Biol 2019; 39:1160–1171.
Garí-Llanes M, García-Nóbrega Y, Chávez-González E, González-Rodríguez E, García-Sáez J, Llanes-Camacho MDC. Biochemical markers and hypertension in children. MEDICC Rev 2019; 21:10–15.
Ma YQ, Thomas GN, Tomlinson B. Association of two apolipoprotein A-I gene MspI polymorphisms with lipid and blood pressure levels. Int J Cardiol 2005; 102:309–314.
Wildman RP, Sutton-Tyrrell K, Newman AB, Bostom A, Brockwell S, Kuller LH. Lipoprotein levels are associated with incident hypertension in older adults. J Am Geriatr Soc 2004; 52:916–921.
Onat A, Can G, Hergenç G, Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond) 2007; 31:1119–1125.
Ganguli D, Das N, Saha I, Chaudhuri D, Ghosh S, Dey S. Risk factors for hypertension in a population-based sample of postmenopausal women in Kolkata, West Bengal, India. Asia Pac J Public Health 2013; 25:388–397.
Kaldmäe M, Viigimaa M, Zemtsovskaja G, Kaart T, Abina J, Annuk M. Prevalence and determinants of hypertension in Estonian adults. Scand J Public Health 2014; 42:504–510.
Glowinska B, Urban M, Koput A, Galar M. New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Atherosclerosis 2003; 167:275–286.
Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, et alINTERHEART Investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation 2019; 139:1472–1482.
Li W, Yu Y, Liang D, Jia EZ. Factors associated with blood pressure variability based on ambulatory blood pressure monitoring in subjects with hypertension in China. Kidney Blood Press Res 2017; 42:267–275.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2014; 384:766–781.
Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res 2017; 122:1–7.
Mosley JD, Gupta DK, Tan J, Yao J, Wells QS, Shaffer CM, et al. Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease. JAMA 2020; 323:627–635.
Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51:1173–1182.
Chung JO, Park SY, Han JH, Cho DH, Chung DJ, Chung MY. Serum apolipoprotein A-1 concentrations and the prevalence of cardiovascular autonomic neuropathy in individuals with type 2 diabetes. J Diabetes Complications 2018; 32:357–361.
Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, et al. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med 2009; 9:319–325.
Carnicer R, Navarro MA, Arbonés-Mainar JM, Arnal C, Surra JC, Acín S, et al. Genetically based hypertension generated through interaction of mild hypoalphalipoproteinemia and mild hyperhomocysteinemia. J Hypertens 2007; 25:1597–1607.
Lee SS, Jhoo YM, Oh DJ, Lee MH, Chung ES, Lee SJ. Plasma apolipoproteins and lipids in normal persons and patients with hypertension. Korean J Intern Med 1986; 1:214–221.
Gabás-Rivera C, Barranquero C, Martínez-Beamonte R, Navarro MA, Surra JC, Osada J. Dietary squalene increases high density lipoprotein-cholesterol and paraoxonase 1 and decreases oxidative stress in mice. PLoS One 2014; 9:e104224.
Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring) 2007; 15:2875–2888.
Wolkowicz P, White CR, Anantharamaiah GM. Apolipoprotein mimetic peptides: an emerging therapy against diabetic inflammation and dyslipidemia. Biomolecules 2021; 11:627.
Wang S, Peng D. Regulation of adipocyte autophagy: the potential anti-obesity mechanism of high density lipoprotein and Apolipoprotein A-I. Lipids Health Dis 2012; 11:131.
Ruan X, Li Z, Zhang Y, Yang L, Pan Y, Wang Z, et al. Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J Cell Mol Med 2011; 15:763–772.
Ricquier D. Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc 2005; 64:47–52.